For example, sotorasib, a KRAS inhibitor that targets KRAS G12C mutations, was approved in 2021 by the FDA for the treatment of advanced non-small-cell lung cancer [64]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.